编辑丨王多鱼排版丨水成文抗 PD-1 联合仑伐替尼（lenvatinib，一种多靶点受体酪氨酸激酶抑制剂）治疗在多种肿瘤中均显示出临床疗效，但潜在的免疫学机制尚不清楚。2025 年 1 月 30 ...

et.al., TCR repertoire diversity of peripheral PD-1+CD8+ T cells predict clinical outcomes after immunotherapy in patients with non-small cell lung cancer, Cancer Immunol. Res. 2020;8(1):146-154 ...

PD-1是CD28家族的一员，在多种免疫细胞中表达，特别是外周组织中活化的CD8+T细胞、CD4+T细胞和B细胞中[2]。PD-1有两个结合配体，PD-L1(B7-H1或CD274 ...

引言肿瘤免疫治疗已是癌症治疗的重要方向，尤其是免疫检查点抑制剂（如PD-1/PD-L1抑制剂）的成功应用，使得癌症治疗迎来了新的曙光。然而，即使这些治疗方法在部分患者中表现出显著疗效，仍有大量患者未能得到有效的治疗。这种现象背后，隐藏着肿瘤免疫逃逸和 ...

A new research paper was published in Oncotarget's Volume 16 on January 20, 2025, titled "Anti-correlation of KLRG1 and PD-1 expression in human tumor CD8 T cells." The study authored by Dr. Steven A.

In mice infected with lymphocytic choriomeningitis virus (LCMV), Ahmed found PD-1 upregulated in functionally-impaired CD8 T cells. The team then showed that preventing PD-1 activation by blocking its ...

In addition, researchers found that targeting BFAR could not only revive the antitumor activity of aged CD8 + T cells, but also enhance the sensibility of PD-1 blockade-based immunotherapy.

那么，能不能在对免疫抑制细胞进行杀伤的同时将补给和兵源精确的投送给免疫激活细胞呢？ 2024年12月2日，清华大学基础医学院、分子肿瘤学全国重点实验室主要成员傅阳心教授团队和中国科学院生物物理研究所彭华研究员（现广州国家实验室研究员）团队在 ...